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Abstract
Aims Obesity doubles the lifetime risk of developing heart failure. Current knowledge on the role of obesity in causing car-
diac dysfunction is insufficient for optimal risk stratification. The aim of this study was first to estimate the prevalence of sub-
clinical cardiac dysfunction in obesity patients and second to investigate the underlying pathophysiology.
Methods and results The CARDIOBESE study is a cross-sectional multicentre study of 100 obesity patients [body mass index
(BMI) ≥ 35 kg/m2] without known cardiovascular disease and 50 age-matched and gender-matched non-obese controls
(BMI ≤ 30 kg/m2). Echocardiography was performed, blood samples were collected, and a Holter monitor was affixed.
Fifty-nine obesity patients [48 (42–50) years, 70% female] showed subclinical cardiac dysfunction: 57 patients had decreased
global longitudinal strain (GLS), and two patients with normal GLS had either diastolic dysfunction or increased brain natri-
uretic peptide (BNP). Only one non-obese control had diastolic dysfunction, and none had another sign of cardiac dysfunction.
Multivariable logistic analysis identified male gender and standard deviation of all NN intervals (SDNN) index, which is a mea-
sure of autonomic dysfunction, as independent significant risk factors for subclinical cardiac dysfunction in obesity patients.
Conclusions There was a high prevalence (61%) of subclinical cardiac dysfunction in obesity patients without known cardio-
vascular disease, which appeared to be best identified by GLS. Subclinical cardiac dysfunction in obesity was linked to auto-
nomic dysfunction and male gender, and not to the presence of traditional cardiac risk factors, increased C-reactive
protein, increased BNP, increased high-sensitivity troponin I, or increased left ventricular mass.
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Introduction
Obesity doubles the lifetime risk of developing heart failure1
and is becoming a global epidemic.2 In 2015, a total of
107.7 million children and 603.7 million adults were obese
[body mass index (BMI) ≥ 30 kg/m2] worldwide. Since 1980,
the prevalence of obesity has doubled in >70 countries.3
Both overweight and obesity are associated with an increased
risk of cardiovascular disease.4 Despite the relatively consis-
tent finding of increased prevalence of heart failure in obe-
sity, the reason for this association remains unclear, and it
seems to be a heterogeneous disorder.5,6 Many factors have
been suggested, such as insulin resistance, hypertension, and
reduced high-density lipoprotein cholesterol (HDL-C).7 How-
ever, the onset of heart failure in obesity patients cannot
be fully explained by the presence of traditional
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cardiovascular risk factors.8 The enormous and growing prev-
alence of obesity warrants efficient screening of obesity pa-
tients with the highest risk of cardiac dysfunction who may
need further risk assessment, follow-up, or even treatment.9
Current knowledge on the role of obesity in causing cardiac
dysfunction is insufficient to optimally develop such strate-
gies for obesity patients.10 Previous studies regarding the de-
tection of the early stages of cardiac dysfunction have shown
the benefits of newer diagnostic techniques such as
speckle-tracking echocardiography over left ventricular (LV)
ejection fraction assessment,11,12 also, for example, in pa-
tients with obstructive sleep apnoea syndrome without overt
LV dysfunction.13 The CARdiac Dysfunction In OBesity—Early
Signs Evaluation (CARDIOBESE) study is the first study in
which conventional and speckle-tracking echocardiography,
blood biomarkers, and Holter monitoring have been com-
bined to study subclinical cardiac dysfunction in a cohort of
obesity patients without known cardiovascular disease and
non-obese controls. The aim of the study was first to identify
the prevalence of subclinical cardiac dysfunction in both
groups and second to investigate the underlying pathophysi-
ology by comparing obesity patients with and without cardiac
dysfunction.
Methods
Study design
The protocol of the CARDIOBESE study has been described
before.14 In short, the CARDIOBESE study is a multicentre
cross-sectional study in which we prospectively enrolled 100
consecutive obesity patients who were referred for bariatric
surgery in the Franciscus Gasthuis & Vlietland (75 patients)
and Maasstad Ziekenhuis (25 patients), both in Rotterdam,
the Netherlands. Patients were enrolled if they were between
35 and 65 years old, had a BMI of ≥35 kg/m2, and gave writ-
ten informed consent. Patients with a suspicion of or known
cardiovascular disease on the basis of the patients’ history (as
determined by questioning the patients and reviewing avail-
able medical files) were excluded. Fifty age-matched and
gender-matched non-obese (BMI < 30 kg/m2) controls, also
without suspicion of cardiovascular disease, were enrolled.
Controls were recruited using advertisements in a local news-
paper or were personnel from the participating hospitals or
family members or friends of personnel.
Conventional and advanced echocardiography was per-
formed, blood samples were collected, and a Holter monitor
was affixed for 24 h for heart rhythm registration in both the
obesity patients and the non-obese controls. This was done
both to quantify the proportion of early signs of cardiac dys-
function and to determine if the prevalence of cardiac dys-
function in obesity patients is increased compared with the
non-obese controls. Also, a broad variety of parameters
known to be related to obesity were collected to investigate
the relation between cardiac dysfunction and obesity. The
study complies with the Declaration of Helsinki, and the pro-
tocol was approved by the Medical Ethics Committee
Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam
e.o. (TWOR).14
Sample size calculation
The combination of parameters used to identify subclinical
cardiac dysfunction has not been investigated in obesity pa-
tients before. A conservative estimate would be that cardiac
dysfunction based on conventional echocardiography is pres-
ent in 20% of obesity patients and 2.5% of age-matched and
gender-matched non-obese controls.15 Given these esti-
mates, to be able to reject the null hypothesis that cardiac
dysfunction rates are equal between patients and controls,
at least 97 obesity patients and 49 non-obese controls have
to be included in the analysis [alpha: 0.05 (two-sided), power:
0.80, 2:1 ratio of patients:controls]. The use of more sensitive
techniques may increase the proportion of non-obese con-
trols with an early sign of cardiac dysfunction. Nevertheless,
the proportion of obesity patients with an early sign of car-
diac dysfunction is expected to increase even more, assuring
that the previous sample size calculation will still suffice.
Transthoracic echocardiography
Two-dimensional greyscale harmonic images were obtained
in the left lateral decubitus position using a commercially
available ultrasound system (EPIQ 7, Philips, the
Netherlands), equipped with a broadband (1–5 MHz) X5-1
transducer. All acquisitions and measurements were per-
formed according to the current guidelines.16,17
Speckle-tracking echocardiography is a new echocardio-
graphic imaging modality that is able to relatively
angle-independently quantify myocardial wall motion.
Greyscale echocardiographic images consist of a speckled
pattern. This pattern is not the actual image of the scatterers
in the tissue itself but the interference pattern generated by
the reflected ultrasound. Each region of the myocardium has
its own unique speckle pattern that remains stable enough to
allow spatial and temporal image processing with selection
and recognition of speckles on the ultrasound image by ded-
icated software packages. The geometric position of the
speckles changes from frame to frame with the surrounding
tissue motion. Therefore, the geometric shift of each speckle
represents local tissue motion, and by tracking these
speckles, myocardial deformation parameters, such as strain,
can be calculated.18 To optimize speckle-tracking echocardi-
ography, apical images were obtained at a frame rate of 60
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to 80 frames/s. Three consecutive cardiac cycles were ac-
quired from all apical views (four-chamber, two-chamber,
and three-chamber). Subsequently, these cycles were trans-
ferred to a QLAB workstation (Version 10.2, Philips, the
Netherlands) for offline speckle-tracking analysis. Offline
analyses were performed by two independent observers. In
end-diastole, automated border tracking was enabled, before
manual adjustment using a ‘point and click approach’ to en-
sure that the endocardial and epicardial borders were in-
cluded in the region of interest. When tracking was
suboptimal, fine-tuning was performed manually. Peak re-
gional longitudinal strain was measured in 17 myocardial re-
gions, and a weighted mean was used to derive global
longitudinal strain (GLS) (Figure 1).16
Blood tests
Non-fasting blood samples were taken both for the study and
as part of regular care, which included sodium, potassium,
calcium, glucose, glycated haemoglobin (HbA1c), creatinine,
estimated glomerular filtration rate (eGFR), alanine
aminotransferase (ALAT), Apo-lipoprotein B100, Lipoprotein
a (Lp(a)), total cholesterol, low-density lipoprotein choles-
terol (LDL-C), HDL-C, triglycerides, ferritin, active vitamin
B12, folic acid, vitamin B1, vitamin B6, albumin, magnesium,
vitamin D, haemoglobin, erythrocytes, thrombocytes,
leucocytes, and thyroid-stimulating hormone (TSH). In addi-
tion to the regular care path, high-sensitivity cardiac troponin
I (hs-cTnI), C-reactive protein, and brain natriuretic peptide
(BNP) were determined. Hs-cTnI was considered positive
when ≥34 ng/L for male and >16 ng/L for female subjects.
Holter monitoring
Heart rhythm was recorded for 24 consecutive hours using a
portable digital recorder (GE HEER Light, USA). The digital re-
corder was connected using stickers that were placed on the
chest. Average heart rate, minimal heart rate, maximum
heart rate, total premature atrial contractions (PACs), total
premature ventricular contractions, the standard deviation
of all NN (often also referred to as RR) intervals (SDNN),
and SDNN index were measured. A 24 h recording of the
Figure 1 Measurement of global longitudinal strain (GLS) by speckle-tracking analysis in an obesity patient [45-year-old woman, body mass index (BMI)
38.4 kg/m2]. (A) Apical four-chamber view with measurement of longitudinal strain. (B) Apical two-chamber view with measurement of longitudinal
strain. (C) Apical three-chamber view with measurement of longitudinal strain. (D) Bull’s eye graph showing longitudinal strain for all myocardial seg-
ments, of which a weighted mean was used to derive GLS.
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SDNN reveals the sympathetic nervous system contribution
to heart rate variability (HRV).19 The SDNN index estimates
the variability due to the factors affecting HRV within a
5 min period. It is calculated by first dividing the 24 h record
into 288 five-minute segments and then calculating the stan-
dard deviation of all NN intervals contained within each
segment.20
Cardiac dysfunction
With the use of echocardiography, Holter monitoring, and
blood tests, cardiac dysfunction was in the current study de-
fined as reduced LV ejection fraction (<52%),16 decreased GLS
(<95th percentile of the non-obese controls, see Statistical
analysis), diastolic dysfunction,17 sustained supraventricular
or (non)sustained ventricular arrhythmia, or an increased
BNP (>30 pmol/L) or hs-cTnI (≥34 ng/L for male and
>16 ng/L for female subjects).
Statistical analysis
Normally distributed data are presented as means and stan-
dard deviation, skewed data as medians and inter-quartile
range, and categorical variables as percentages and frequen-
cies. The normality of the data was checked by the Shapiro–
Wilk test. Differences in both the clinical characteristics and
parameters of cardiac function between obesity patients
and the non-obese controls were estimated by using general-
ized linear mixed models with obesity as the independent
variable, and parameters were entered consecutively as the
dependent variable, and the matched pairs were used as ran-
dom intercepts. Missing variables were omitted. Differences
in both clinical characteristics and parameters of cardiac func-
tion in obesity patients were tested by univariable logistic re-
gression with cardiac dysfunction as the dependent variable.
The Benjamini–Hochberg procedure, with a 5% false discov-
ery rate, was used to correct for the multiple testing.21
Patient characteristics statistically significant different be-
tween obesity patients with and without cardiac dysfunction
in the univariable analyses were added to multivariable logis-
tic regression analysis (method: backward stepwise analysis).
Predicted probabilities of cardiac dysfunction in obesity pa-
tients obtained from the model were used to construct a re-
ceiver operating characteristic (ROC) curve, and the area
under the ROC curve was calculated as an overall measure
of discriminative ability. Sensitivity, specificity, positive pre-
dictive value, and negative predictive value and their 95%
confidence intervals were calculated. A two-tailed P-value
of <0.05 was considered statistically significant. Statistical
analyses were performed with SPSS Version 25.0 and R Ver-
sion 3.6.0.
Results
Clinical characteristics of obesity patients and
non-obese controls
Table 1 and Figure 2A show the characteristics of the obe-
sity patients (n ¼ 100) and the non-obese controls
(n ¼ 50). Obesity patients had significantly increased
weight, BMI, systolic blood pressure, waist circumference,
and heart rate. Obesity patients also had significantly more
frequent co-morbidities such as diabetes mellitus and
hypertension and more often used medication
(angiotensin-converting enzyme inhibitors/angiotensin II re-
ceptor blockers, diuretics, and oral anti-diabetics). Blood
tests showed that obesity patients had significantly in-
creased C-reactive protein, leucocytes, glucose, HbA1c,
Apo-lipoprotein B100, triglycerides, and active vitamin
B12. HDL-C, albumin, and vitamin D were decreased in obe-
sity patients. Echocardiography showed an increased LV
mass in obesity patients, but when corrected for the body
surface area (LV mass index), there was no significant dif-
ference between groups. Holter monitoring showed a
significantly increased average and minimal heart rate in
obesity patients. Obesity patients also had a significantly
decreased SDNN and SDNN index.
Parameters of cardiac function in obesity patients
and non-obese controls
GLS was available in 49 non-obese controls and 94 obesity
patients (unavailable in the other subjects owing to insuffi-
cient echocardiographic image quality). Obesity patients
had a significantly decreased GLS. With the use of a
cut-off value of 16.9% (95th percentile of the non-obese
controls), 57 (61%) obesity patients showed decreased GLS
than did none of the controls (P < 0.001). The LV ejection
fraction (57 ± 7 vs. 65 ± 5%, P < 0.001) was decreased as
well, although only 24 (25% of 95 patients with available
LV ejection fraction) of the obesity patients had an LV ejec-
tion fraction <52% (all with GLS < 16.9%). Also, obesity pa-
tients tended to have diastolic dysfunction more
frequently (11% vs. 2%, P ¼ 0.09). The septal e′ velocity
and lateral e′ velocity were decreased. Levels of BNP and
hs-cTnI were comparable. One obesity patient had an epi-
sode of asymptomatic atrial flutter during 5 h recorded dur-
ing Holter monitoring.
In total, 60 obesity patients showed at least one subclinical
sign of cardiac dysfunction: 57 had a decreased GLS, one had
diastolic dysfunction without an available GLS, one had a nor-
mal GLS (17.3%) but an increased BNP (49 pmol/L, normal
value < 30 pmol/L), and one had both a positive hs-cTnI and
a paroxysmal atrial flutter (GLS 18.6% in this patient). The
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Table 1 Clinical characteristics of the study population and parameters of cardiac function
Non-obese (n ¼ 50) Obese (n ¼ 100) P-value
Clinical characteristics
General characteristics
Age (years) 50 (40–59) 48 (42–50) 0.02*
Female (%) 35 (70%) 70 (70%) >0.99
Physical examination
Length (m) 1.74 ± 0.1 1.71 ± 0.1 0.08
Weight (kg) 76 (64–82) 123 (115–135) <0.001*
BMI (kg/m2) 25 (22–28) 42 (40–46) <0.001*
Systolic BP (mmHg) 127 (118–136) 140 (127–157) <0.001*
Diastolic BP (mmHg) 78 (71–82) 79 (72–88) 0.11
Waist circumference (cm) 79 (74–89) 131 (125–140) <0.001*
Heart rate (b.p.m.) 64 ± 9 80 ± 13 <0.001*
Co-morbidity
Diabetes mellitus 0 22 (22%) 0.007*
Hypertension 4 (8%) 32 (32%) 0.003*
Hypercholesterolaemia 5 (10%) 18 (18%) 0.21
Current smoking 7 (14%) 17 (17%) 0.63
COPD 1 (2%) 5 (5%) 0.39
OSAS 1 (2%) 12 (12%) 0.07
Medication
Beta-blockers 0 8 (8%) 0.03
ACE inhibitors/ARBs 2 (4%) 24 (24%) 0.008*
Calcium channel blockers 0 12 (12%) 0.04
Statins 3 (6%) 20 (20%) 0.03
Diuretics 1 (2%) 18 (18%) 0.02*
Insulin 0 7 (7%) 0.04
Oral anti-diabetics 0 15 (15%) 0.02*
Blood tests
C-reactive protein (mg/L) 1 (0–2) 6 (4–10) <0.001*
Glucose (mmol/L) 5.1 (4.7–5.5) 5.4 (4.8–6.2) 0.006*
HbA1c (mmol/mol) 35 (33–37) 39 (35–47) <0.001*
Creatinine (μmol/L) 69 (65–75) 72 (65–78) 0.35
eGFR (mL/min/1.73 m2) 74 (69–79) 90 (79–90) <0.001*
ALAT (U/L) 22 (15–32) 28 (20–37) 0.64
Apo-lipoprotein B100 (g/L) 0.90 (0.75–1.07) 1.05 (0.91–1.30) 0.007*
Lipoprotein (a) (mg/L) 172 (52–367) 167 (71–522) 0.80
Total cholesterol (mmol/L) 5.2 ± 1 5.3 ± 1 0.55
LDL cholesterol (mmol/L) 3.0 ± 1.0 3.2 ± 0.9 0.24
HDL cholesterol (mmol/L) 1.4 (0.94–1.80) 1.1 (1.0–1.4) <0.001*
Triglycerides (mmol/L) 1.25 (0.9–1.8) 1.74 (1.3–2.6) 0.01*
Ferritin (μg/L) 79 (34–149) 90 (49–176) 0.82
Active vitamin B12 (pmol/L) 96 (71–127) 101 (70–130) 0.002*
Folic acid (nmol/L) 17 (12–22) 12 (8–16) 0.002*
Vitamin B1 (nmol/L) 130 (98–144) 140 (118–157) 0.03
Vitamin B6 (nmol/L) 84 (74–114) 69 (52–83) 0.43
Albumin (g/L) 43 ± 2 41 ± 4 <0.001*
Magnesium (mmol/L) 0.85 ± 0.05 0.81 ± 0.07 <0.001*
Vitamin D (nmol/L) 60 (42–75) 39 (27–61) <0.001*
Haemoglobin (mmol/L) 8.6 (8.3–9.1) 8.8 (8.2–9.2) 0.21
Erythrocytes (×1012/L) 4.6 ± 0.4 4.9 ± 0.4 <0.001*
Thrombocytes (×109/L) 231 ± 48 261 ± 70 0.009*
Leucocytes (×109/L) 5.9 (5.0–7.4) 8.5 (6.9–9.6) <0.001*
TSH (mU/L) 1.60 (1.1–1.9) 1.63 (1.2–2.4) 0.03
Echocardiography parameters
LVM (g) 148 (117–175) 194 (149–231) <0.001*
LVM index (g/m2) 79 (62–88) 76 (64–92) 0.16
Holter monitoring
Average heart rate (b.p.m.) 73 ± 10 83 ± 10 <0.001*
Minimal heart rate (b.p.m.) 48 (41–50) 52 (47–56) <0.001*
Maximum heart rate (b.p.m.) 138 (125–155) 136 (126–150) 0.62
SDNN (ms) 160 (130–194) 101 (71–141) <0.001*
SDNN index (ms) 63 (49–79) 47 (38–58) <0.001*
Parameters of cardiac function
Echocardiographic parameters
Mitral inflow E-wave (cm/s) 73 ± 13 69 ± 14 0.06
Mitral inflow A-wave (cm/s) 64 ± 14 70 ± 14 0.003*
(Continues)
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latter patient was diagnosed with acromegaly after inclusion.
We, therefore, decided to exclude this patient from the fol-
lowing sub-analysis, focusing specifically on obesity patients
with cardiac dysfunction.
Characteristics of obesity patients with subclinical
signs of cardiac dysfunction
Table 2 and Figure 2B display the characteristics of obesity pa-
tients with (n¼ 59) and without (n¼ 40) cardiac dysfunction.
Obesity patients with cardiac dysfunction were more often
male and had an increased heart rate. There were no signifi-
cant differences regarding the prevalence of co-morbidities
and medication use.
Blood tests showed increased glucose and ALAT in obesity
patients with cardiac dysfunction. Also, these patients had
decreased levels of LDL-C and HDL-C. Hs-cTnI and C-reactive
protein were not significantly different.
Obesity patients with cardiac dysfunction tended to have
an increased LV mass and LV mass index. They also had more
often diastolic dysfunction. Holter monitoring showed a de-
creased SDNN index in obesity patients with cardiac
dysfunction.
Odds ratios and predictive model of cardiac
dysfunction in obesity patients
Univariable logistic regression analysis showed that cardiac
dysfunction was associated with male gender, SDNN index,
SDNN, length, waist circumference, heart rate, glucose, ALAT,
total cholesterol, LDL-C, HDL-C, and erythrocytes. The multi-
variable logistic analysis identified male gender and SDNN in-
dex as independent significant risk factors for subclinical
cardiac dysfunction in obesity patients (Table 3). The ROC
curve is shown in Figure 3. The area under the ROC curve
was 0.81 (95% CI: 0.71–0.91, P < 0.001). Sensitivity was 74%
(95% CI: 57–86%), specificity 62% (95% CI: 45–77%), positive
predictive value 67% (95% CI: 50–80%), and negative predic-
tive value 70% (95% CI: 51–84%).
Discussion
The main findings of the current study are (i) that there is a
high prevalence (61%) of subclinical cardiac dysfunction in
obesity patients (BMI ≥ 35 kg/m2) without suspicion of or
known cardiovascular disease; (ii) in the vast majority of pa-
tients with subclinical cardiac dysfunction, this was identified
Table 1 (continued)
Non-obese (n ¼ 50) Obese (n ¼ 100) P-value
E/A ratio 1.20 (0.97–1.4) 0.98 (0.87–1.1) <0.001*
Septal e′ velocity (cm/s) 9 (7–10) 8 (7–9) 0.03
Lateral e′ velocity (cm/s) 13 (10–15) 10 (8–13) <0.001*
E/e ratio 8.0 (7.3–10) 8.7 (7.2–10) 0.25
Deceleration time (s) 0.18 (0.16–0.20) 0.19 (0.17–0.22) 0.25
LA volume index (mL/m2) 26 ± 6 26 ± 8 0.88
TR velocity (cm/s) 106 (89–199) 99 (90–132) 0.16
Diastolic dysfunction (%) 1 (2%) 11 (11%) 0.09
LV ejection fraction (%) 65 ± 5 57 ± 7 <0.001*
GLS (%) 20 (21 to 19) 16 (18 to 14) <0.001*
Blood tests
BNP (pmol/L) 6 (3–9) 5 (3–8) 0.59
Hs troponin I positive (%) 0 1 (1%) 0.37
Holter monitoring
Total PAC per 24 h (n) 9 (3–23) 10 (2–34) 0.11
Total PVC per 24 h (n) 4 (1–17) 3 (0–22) 0.69
Supraventricular arrhythmia (%) 0 1 (1%) 0.37
Ventricular arrhythmia (%) 1 (2%) 0 0.16
ACE, angiotensin-converting enzyme; ALAT, alanine aminotransferase; ARBs, angiotensin II receptor blockers; A-wave, late diastolic
transmitral flow velocity; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; e′, early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; E-wave, early diastolic transmitral flow veloc-
ity; GLS, global longitudinal strain; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LA volume index, left atrial volume
index; LDL, low-density lipoprotein; LV, left ventricular; LVM index, left ventricular mass index; LVM, left ventricular mass; OSAS, obstruc-
tive sleep apnoea syndrome; PAC, premature atrial contraction; PVC, premature ventricular contraction SDNN index, mean of the standard
deviations of all the NN intervals for each 5 min segment of a 24 h heart rate variability recording; SDNN, standard deviation of NN
intervals; TR velocity, tricuspid regurgitation; TSH, thyroid-stimulating hormone.
Differences between obesity patients and non-obese controls. Values represent mean ± SD, median (Q1–Q3) or n (%). P-values displayed
were analysed by using generalized linear mixed models. Global longitudinal strain was available in 49 non-obese controls and in 94
obesity patients. Left ventricular ejection fraction was available in 49 non-obese controls and in 95 obesity patients.
Bold values are statistically significant at p<0.05; the bold values marked by * remain statistically significant after Benjamini – Hochberg
correction.
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by abnormal GLS, clearly more than by other echocardio-
graphic parameters, arrhythmias, increased BNP or
high-sensitivity troponin I (hs-TnI); and (iii) decreased HRV
as measured by SDNN index and male gender are predictors
of subclinical cardiac dysfunction in obesity patients.
The association between abnormalities in cardiac struc-
ture and function is known in obesity patients.1 Because
of the ongoing obesity epidemic, efficient screening for
(subclinical) cardiac dysfunction in these patients is
needed.22 The current knowledge of the early signs of car-
diac dysfunction in obesity patients is not optimal to de-
velop such screening tools.
In our study, we were unable to identify subclinical cardiac
dysfunction in obesity patients by Holter monitoring or
assessment of hs-cTnI and BNP. The frequency of extrasystole
was not increased, and although obesity is a known risk
factor for atrial fibrillation,23 none of the obesity patients
showed atrial fibrillation during the 24 h Holter monitoring.
There was one patient with an atrial flutter and a positive
hs-cTnI, but he was diagnosed with acromegaly after
inclusion and therefore does not represent the typical obesity
patients without known cardiac disease.
However, we were able to identify a high prevalence of
subclinical cardiac dysfunction on the basis of a decreased
GLS by advanced echocardiography in 57 (61% of the 94 obe-
sity patients with available GLS) of the obesity patients. GLS
performed much better as compared with conventional echo-
cardiography parameters such as LV ejection fraction (de-
creased in 29% of the obesity patients) and diastolic
function (abnormal in only 11% of the obesity patients). Cur-
rently, GLS assessment by speckle-tracking echocardiography
is broadly available, as echo machines from all well-known
vendors are generally equipped with speckle-tracking soft-
ware. Strain can be assessed in three directions (longitudinal,
circumferential, and radial), with longitudinal strain known to
be the most reproducible. It is therefore recommended to
use GLS as a parameter of LV systolic function.16 Recently,
we demonstrated that the assessment of GLS is feasible and
reproducible in obesity patients as well.24 As said, in the cur-
rent study, we identified GLS as the best parameter to diag-
nose cardiac dysfunction in obesity patients. Therefore,
when looking for subclinical cardiac abnormalities in these
patients, GLS assessment by speckle-tracking echocardiogra-
phy seems to be the best diagnostic technique.
Figure 2 Difference in clinical characteristics and cardiac dysfunction parameters in (A) obesity patients vs. non-obese controls. (B) Obesity patients
with vs. obesity patients without cardiac dysfunction. Arrows indicate whether parameters were increased or decreased in obesity patients (A) or
in obesity patients with cardiac dysfunction (B). Bold and underlined parameters are identified as significant risk factors for cardiac dysfunction in obe-
sity patients by multivariate analysis. ACE, angiotensin-converting enzyme; ALAT, alanine aminotransferase; ARBs, angiotensin II receptor blockers;
BMI, body mass index; CRP, C-reactive protein; e′, early diastolic mitral annular velocity; E-wave, early diastolic transmitral flow velocity; GLS, global
longitudinal strain; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; LV, left ventricu-
lar; OSAS, obstructive sleep apnoea syndrome; SDNN, standard deviation of NN intervals.
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Table 2 Clinical characteristics and parameters of cardiac function in obesity patients with and without cardiac dysfunction
Obese with normal cardiac function (n ¼ 40) Obese with cardiac dysfunction (n ¼ 59) P-value
Clinical characteristics
General characteristics
Age (years) 47 (42–52) 49 (42–56) 0.53
Female (%) 35 (88%) 35 (59%) 0.004*
Physical examination
Length (m) 1.69 ± 0.1 1.73 ± 0.1 0.045
Weight (kg) 123 (115–132) 124 (114–138) 0.28
BMI (kg/m2) 43 (40–46) 42 (40–45) 0.56
Systolic blood pressure (mmHg) 139 ± 21 144 ± 20 0.08
Diastolic blood pressure (mmHg) 75 (70–84) 80 (73–89) 0.06
Waist circumference (cm) 128 (122–134) 137 (127–141) 0.048
Heart rate (b.p.m.) 76 ± 11 83 ± 14 0.019*
Co-morbidity
Diabetes mellitus 8 (20%) 13 (22%) 0.81
Hypertension 11 (28%) 20 (34%) 0.27
Hypercholesterolaemia 8 (20%) 10 (17%) 0.89
Current smoking 7 (18%) 9 (15%) 0.77
COPD 3 (8%) 2 (3%) 0.37
OSAS 3 (8%) 8 (14%) 0.35
Medication
Beta-blockers 3 (8%) 5 (9%) 0.36
ACE inhibitors/ARBs 10 (27%) 13 (23%) 0.53
Calcium channel blockers 3 (8%) 7 (12%) 0.13
Statins 5 (13%) 14 (25%) 0.12
Diuretics 6 (16%) 11 (19%) 0.13
Insulin 2 (5%) 5 (9%) 0.51
Oral anti-diabetics 5 (13%) 9 (16%) 0.70
Blood tests
C-reactive protein (mg/L) 7 (3–10) 6 (4–11) 0.70
Glucose (mmol/L) 5.0 (4.6–5.6) 5.6 (5.1–6.7) 0.01*
HbA1c (mmol/mol) 37 (35–43) 40 (36–51) 0.05
Creatinine (μmol/L) 68 (64–78) 73 (66–77) 0.32
eGFR (mL/min/1.73 m2) 87 (79–90) 90 (80–90) 0.43
ALAT (U/L) 23 (16–33) 31 (22–45) 0.003*
Apo-lipoprotein B100 (g/L) 1.12 ± 0.3 1.04 ± 0.3 0.67
Lipoprotein (a) (mg/L) 190 (65–599) 149 (71–386) 0.10
Total cholesterol (mmol/L) 5.5 ± 0.8 5.1 ± 1.1 0.025
LDL cholesterol (mmol/L) 3.5 ± 0.8 3.0 ± 0.9 0.003*
HDL cholesterol (mmol/L) 1.3 (1.0–1.5) 1.1 (1.0–1.3) 0.009*
Triglycerides (mmol/L) 1.4 (1.0–2.0) 2.1 (1.5–3.0) 0.09
Ferritin (μg/L) 87 (49–136) 92 (58–189) 0.14
Active vitamin B12 (pmol/L) 93 (61–128) 108 (71–197) 0.22
Folic acid (nmol/L) 11 (8–16) 12 (9–16) 0.45
Vitamin B1 (nmol/L) 13 ± 29 145 ± 22 0.08
Vitamin B6 (nmol/L) 65 (54–91) 70 (52–80) 0.39
Albumin (g/L) 42 (40–44) 42 (39–44) 0.83
Magnesium (mmol/L) 0.81 ± 0.06 0.81 ± 0.07 0.45
Vitamin D (nmol/L) 39 (28–60) 39 (27–61) 0.95
Haemoglobin (mmol/L) 8.6 (8.0–9.0) 8.9 (8.4–9.3) 0.11
Erythrocytes (×1012/L) 4.8 ± 0.4 5.0 ± 0.3 0.03
Thrombocytes (×109/L) 270 ± 54 255 ± 79 0.22
Leucocytes (×109/L) 8.4 (6.8–9.4) 8.5 (7.0–10.2) 0.48
TSH (mU/L) 1.5 (1.2–2.5) 1.7 (1.2–2.4) 0.94
Echocardiographic parameters
LVM (g) 169 (140–215) 203 (156–241) 0.10
LVM index (g/m2) 72 (59–88) 81 (67–94) 0.16
Holter monitoring
Average heart rate (b.p.m.) 81 ± 9 83 ± 10 0.35
Minimal heart rate (b.p.m.) 50 (46–55) 53 (47–56) 0.66
Maximum heart rate (b.p.m.) 142 (129–152) 132 (125–146) 0.06
SDNN (ms) 121 ± 48 99 ± 42 0.026
SDNN index (ms) 54 ± 16 45 ± 14 0.015*
Parameters of cardiac function
Echocardiographic parameters
Mitral inflow E-wave (cm/s) 75 ± 15 65 ± 12 0.007*
(Continues)
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So far, the pathophysiology of obesity leading to cardiac
dysfunction is incompletely understood, and it was hypothe-
sized that it is most likely multifactorial.3,25 While previous
studies examined the association between heart failure and
obesity,1,26 the CARDIOBESE study is the first to investigate
the relation between subclinical cardiac dysfunction and
obesity using a combination of techniques to simultaneously
investigate different aspects that may all play a role. The
transthoracic echocardiogram may identify direct local effects
of obesity such as increased LV mass, systemic influences
caused by secretion of adipokines by the fat tissue may be re-
vealed by the blood tests, and the Holter monitor may iden-
tify autonomic dysfunction by assessment of HRV.
In our study, there were no differences between obesity
patients with and without subclinical cardiac dysfunction re-
garding the presence of traditional cardiac risk factors, such
as diabetes mellitus, hypertension, and hypercholesterolae-
mia. These results are consistent with previous studies, which
showed that the onset of heart failure in obesity cannot be
fully explained by these risk factors.27 Also, obesity patients
are known to have a state of chronic low-grade
inflammation.28 Although increased circulating levels of
C-reactive protein were observed in obesity patients com-
pared with non-obese controls, there was no difference be-
tween obesity patients with and without subclinical cardiac
dysfunction. Therefore, at least as far as C-reactive protein
reflects systemic inflammation, this was not likely to be an ex-
planation of subclinical cardiac dysfunction in our patients. In-
creased cardiac filling pressures or cardiomyocyte damage
have been suggested to play a role29; however, BNP and
hs-cTnI were comparable between obesity patients and
non-obese controls and between obesity patients with and
Table 2 (continued)
Obese with normal cardiac function (n ¼ 40) Obese with cardiac dysfunction (n ¼ 59) P-value
Mitral inflow A-wave (cm/s) 70 ± 11 70 ± 15 0.68
E/A ratio 1.1 (0.92–1.20) 0.96 (0.80–1.10) 0.029
Septal e′ velocity (cm/s) 8 ± 2 8 ± 2 0.22
Lateral e′ velocity (cm/s) 12 ± 3 10 ± 3 0.002*
E/e′-ratio 9.1 (7.5–10.3) 8.4 (6.9–9.7) 0.27
Deceleration time (s) 0.19 ± 0.04 0.19 ± 0.04 0.93
LA volume index (mL/m2) 25 ± 7 26 ± 8 0.52
TR velocity (cm/s) 113 (91–140) 93 (86–125) 0.55
Diastolic dysfunction (%) 0 10 (17%) 0.001*
LV ejection fraction (%) 62 ± 6 54 ± 7 <0.001*
GLS 19.2 ± 1.3 14.4 ± 2.1 <0.001*
Blood tests
BNP (pmol/L) 6 (4–11) 4 (3–6) 0.29
hs-troponin I positive (%) 0 0
Holter monitoring
Total PAC per 24 h 12 (3–38) 8 (2–27) 0.42
Total PVC per 24 h 2 (0–16) 3 (0–28) 0.98
Supraventricular arrhythmia (%) 0 0
Ventricular arrhythmia (%) 0 0
ACE, angiotensin-converting enzyme; ALAT, alanine aminotransferase; ARBs, angiotensin II receptor blockers; A-wave, late diastolic
transmitral flow velocity; BMI, body mass index; BNP, brain natriuretic peptide; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; e′, early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; E-wave, early diastolic transmitral flow veloc-
ity; GLS, global longitudinal strain; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LA volume index, left atrial volume in-
dex; LDL, low-density lipoprotein; LV, left ventricular; LVM index, left ventricular mass index; LVM, left ventricular mass; OSAS,
obstructive sleep apnoea syndrome; PAC, premature atrial contraction; PVC, premature ventricular contraction SDNN index, mean of
the standard deviations of all the NN intervals for each 5 min segment of a 24 h heart rate variability recording; SDNN, standard deviation
of NN intervals; TR velocity, tricuspid regurgitation; TSH, thyroid-stimulating hormone.
Values represent mean ± SD, median (Q1–Q3) or n (%). P-values displayed were analysed by using univariable logistic regression.
Bold values are statistically significant at p<0.05; the bold values marked by * remain statistically significant after Benjamini – Hochberg
correction.
Table 3 Univariable and multivariable logistic regression analysis
in obesity patients, with presence of cardiac dysfunction as the de-
pendent variable
Variable Univariate P-value Multivariate P-value
Male gender 0.004 0.001
SDNN index 0.015 0.015
SDNN 0.026
Waist circumference 0.048
Heart rate 0.019
Glucose 0.01
ALAT 0.003
Total cholesterol 0.025
LDL cholesterol 0.003
HDL cholesterol 0.009
Erythrocytes 0.03
Length 0.045
ALAT, alanine aminotransferase; SDNN index, mean of the stan-
dard deviations of all the NN intervals for each 5 min segment of
a 24 h heart rate variability recording; SDNN, standard deviation
of NN intervals.
Variables displayed were statistically significant different between
obesity patients with and without cardiac dysfunction. Multivariate
logistic regression analysis; method: backward stepwise analysis.
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without cardiac dysfunction in our study. Finally, the LV mass
and LV mass index were comparable between obesity pa-
tients with and without subclinical cardiac dysfunction.
Therefore, the local effect of increased LV mass does not
seem to play a major role in obesity leading to subclinical car-
diac dysfunction.
Nevertheless, the SDNN index as a measure of HRV and
thereby of autonomic dysfunction was strikingly different be-
tween obesity patients with and without subclinical cardiac
dysfunction and was identified as an independent risk factor
for cardiac dysfunction by multivariable analysis. The SDNN
index estimates the variability due to the factors affecting
HRV within a 5 min period.30 Even a slight variation in the au-
tonomic regulation of the heart changes the heart rate and
rhythm.31 The analysis of HRV thereby provides a
non-invasive tool to characterize autonomic function. De-
pressed HRV has been confirmed to be a prognostic marker
and is correlated with morbidity and mortality.32–34 Further-
more, sympathetic nervous system dysfunction is crucial in
the development of heart failure.35 Previous studies already
described a decreased HRV in obesity patients,31,36 linking
this to inflammatory processes.37,38 However, our study not
only confirmed the presence of a decreased HRV in obesity
patients, but it is also the first to show that decreased HRV
may play a crucial role in the development of cardiac dysfunc-
tion in these patients. Therefore, the analysis of HRV may be
a useful and simple non-invasive method to further investi-
gate the effect of obesity on cardiac function.
The multivariable analysis identified not only SDNN index
but also male gender as a significant risk factor for cardiac
dysfunction in obesity patients. Previous studies already de-
scribed an association between obesity and more severe
heart failure symptoms in male patients compared with fe-
male patients.39 Also, overweight and obese men have higher
adjusted mortality than normal-weight men, whereas a BMI
in the overweight range was associated with a survival bene-
fit in women.40 However, the reason for these findings is not
clear. It cannot be excluded that there are unidentified con-
founders related to gender that may explain the suggested
relationship between male gender and cardiac dysfunction
in obesity in our study. Further studies are needed to clarify
this issue.
Limitations
GLS was missing in seven obesity patients because of insuffi-
cient image quality. This may have affected the identified
prevalence of cardiac dysfunction. In addition, cardiac mag-
netic resonance could be of added value, when investigating
myocardial characteristics. However, this was not available in
the CARDIOBESE study. Also, the study contained a relatively
large number of women (70%), which may have influenced
the observed relationship between gender and subclinical
cardiac dysfunction.
Figure 3 ROC curve for the prediction model for cardiac dysfunction in obesity patients. Model; combination of SDNN, SDNN index, gender, ALAT,
glucose, and triglycerides. Area under the curve ¼ 0.72 (95% CI: 0.61–0.82, P < 0.001). ALAT, alanine aminotransferase; ROC, receiver operating char-
acteristic; SDNN, standard deviation of all NN intervals.
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When studying HRV, one can select several parameters.41
In our study, we only used SDNN and SDNN index as
markers of HRV to limit the total number of parameters
studied. They were chosen because no currently recognized
HRV measure provides better prognostic information than
the time domain HRV measures assessing overall HRV.41 In
parallel, we only used C-reactive protein and leucocytes as
inflammatory markers, also to limit the total number of pa-
rameters studied and because of limited testing that can be
done in our clinical laboratory. To further investigate the
role of inflammation, further studies are needed. Also,
blood samples were obtained in the non-fasting state,
which could have influenced our results. Finally, although
obesity is usually defined as a BMI ≥ 30 kg/m2, all patients
in our study had a BMI ≥ 35 kg/m2, because they were in-
cluded at the outpatient clinic for screening for bariatric sur-
gery (BMI ≥ 35 kg/m2 is a condition to qualify for bariatric
surgery). Therefore, the conclusions may only be applied
to morbidly obese patients and not to obesity patients in
general.
Conclusions
There was a high prevalence (61%) of subclinical cardiac dys-
function in obesity patients without known cardiovascular
disease, which appeared to be best identified by GLS. Subclin-
ical cardiac dysfunction in obesity was linked to autonomic
dysfunction and male gender and not to the presence of tra-
ditional cardiac risk factors, increased C-reactive protein, in-
creased BNP, increased hs-TnI, or increased LV mass.
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